Objectives: Recently, three large Chinese cohort studies showed that 7.5% to 15.5% of patients with cervical carcinoma had negative high-risk human papillomavirus (hrHPV) test results on prior cytology specimens. These studies raise the question as to whether these negative hrHPV results represent truly hrHPV-negative carcinomas or false-negative hrHPV test results due to limitations in the testing of cytology specimens. This is increasingly an important question with increasing push to use hrHPV testing alone to screen for cervical cancer.
Methods:
We investigated the hrHPV status on the surgical specimens from these same patients with cervical carcinoma using three polymerase chain reaction methods and a linear assay genotyping method.
Results: A variety of HPV genotypes were detected in 28 (45.9%) of 61 cases, all belonging to carcinogenic or possibly carcinogenic categories. HPV 16 was the most common genotype detected in positive cases (66.7%). HPV was detected in 25 (50%) of 50 squamous cell carcinomas and two (66.7%) of three adenosquamous carcinomas and only one (12.5%) of eight endocervical adenocarcinomas.
Conclusions: Our findings demonstrate that negative hrHPV testing on cervicovaginal cytology specimens in women later diagnosed with cervical carcinoma can be explained by the occurrence of truly HPV-negative carcinomas in more than half of patients. These results should be considered in the development of future cervical cancer screening guidelines.
Cervical cancer is the second most common type of cancer among women in developing countries. It is thought that virtually all cervical cancers and their precursors are caused by persistent high-risk human papillomavirus (hrHPV) infection. Liquid-based hrHPV testing has been suggested to have a higher sensitivity than Papanicolaou (Pap) cytology test in detecting cervical precancerous lesions, and the US Food and Drug Administration recently approved the Cobas human papillomavirus (HPV) test (Roche Molecular Diagnostics, Pleasanton, CA) for use as a first-line primary screening test for cervical cancer in women aged 25 years or older. [1] [2] [3] [4] At the same time that there is a push for hrHPV testing alone to be used as a first-line screening test for cervical Upon completion of this activity you will be able to:
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cancer, multiple studies have found a broad range of hrHPV-negative rates (10%-30%) in cervical cytology specimens from patients with cervical cancer. [5] [6] [7] [8] [9] [10] [11] [12] Our recent multicenter study in the United States indicated HPVnegative rates of 9%, 23%, and 25% less than 1 year, 1 to 3 years, and 3 to 5 years, respectively, before histologic diagnoses of cervical cancer. 13 Additional study from Quest also showed HPV-negative rates of 19% within 1 year in 526 patients with invasive cervical cancer.
14 China accounts for 14% of the world's annual incidence of cervical cancer, and a large pooled analysis in China suggests that the cervical cancer incidence in China may be higher than the currently estimated incidence of 9.6 per 100,000 women. 15, 16 Recently, we published three independent studies from China and demonstrated that the hrHPV test (Hybrid Capture 2 (Qiagen, Gaithersburg, MD) on Pap cytology specimens) was negative in 15.5% (64/477), 7.5% (32/427), and 9.8% (13/133) of patients with invasive cervical carcinoma, respectively, from the Obstetrics and Gynecology Hospital of Fudan University (OGHFU), Guangzhou Kingmed Diagnostics, and China-Japan Friendship Hospital. [17] [18] [19] The potential reasons for negative hrHPV testing in the setting of cervical cancer screening include sampling variability, low viral load in some cancers, rapidly developing cervical carcinomas that arise between screening intervals, and the rare occurrence of truly hrHPV-negative cervical carcinomas. 20, 21 In this study, we aimed to investigate whether hrHPV DNA can be detected by different molecular methods in surgical tissues resected from patients with invasive cervical cancer with prior hrHPV testing on cytology specimens in the previously published cohorts and therefore determine whether prior negative hrHPV test results are true negative or false negative in these patients.
Materials and Methods

Patient Accrual
Based on the cohorts in our previous studies from the OGHFU and Guangzhou Kingmed Diagnostics in China, cervical cancer cases with negative hrHPV testing (HC2 test) on cytology specimens 1 year before histologic diagnosis and available resected tumor tissue were included in the current study. All surgical pathology slides were reviewed by at least two surgical pathologists to confirm the diagnosis and sufficient tumor tissue for HPV molecular tests. A total of 61 cases with prior negative hrHPV testing on cytology specimens and available paraffin-embedded tissues were selected, including 50 squamous cell carcinomas, eight adenocarcinomas (five usual types, two minimal deviation carcinomas, and one clear cell carcinoma), and three adenosquamous carcinomas Image 1 . The mean patient age was 47 years, with a range of 27 to 78 years. The mean interval between negative hrHPV testing on cytology specimens and histologic diagnosis of cervical cancer was 1.8 months (range, 0.2-12 months).
DNA Extraction
Paraffin blocks were processed under strict conditions to avoid contamination. DNA was extracted from 10 paraffin sections (4 lm each) from a block of each patient using the QIAamp DNA FFPE tissue kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's protocol. Briefly, 1 mL xylene was added to the centrifuge tube and vortexed vigorously for 10 seconds and centrifuged. The supernatant was removed, 1 mL of 100% ethanol was added, and the sample was mixed and centrifuged. Again the supernatant was removed, and all residual ethanol was allowed to evaporate. Animal tissue lysis (ATL) buffer and protein K were added and incubated at 56 C and 90 C for 1 hour each. ATL buffer was then added and the lysate was transferred to the MinElute column (kit provided), centrifuged, and washed twice. DNA was then eluted using animal tissue elution buffer and samples were stored at -20 C for later use.
Polymerase chain reaction (PCR)-based HPV DNA detection and HPV genotyping were performed independently at two different laboratories simultaneously and doubleblindly, without knowing the results by each other.
PCR for HPV DNA Detection
To increase sensitivity, PCR for HPV detection was performed with three commonly used consensus primer sets (GP5þ/6þ, MY09/11, and SPF1/2) for different L1 regions of the viral genome Table 1 . Conditions for the three PCR methods were similar to previous publications with some adjustments as follows:
Both MY09/11 and GP5þ/6þ were performed in a final reaction volume of 20 lL, containing 3 lL isolated DNA, 2 lL 10Â buffer, 0.8 lL each dNTP, 0.4 lL each of forward and reverse primers, and 1.0 U Taq DNA polymerase (Genebase Bioscience, Guangzhou, China). PCR temperature cycling for MY09/11 was as follows: preheat for 5 minutes at 94 C followed by 40 cycles of 30 seconds at 94 C, 1 minute at 45 C, and 1 minute at 72 C and a final extension of 7 minutes at 72 C. PCR conditions with the GP5þ/6þ primer set were as follows: preheat for 10 minutes at 94 C followed by 40 cycles of 1 minute at 94 C, 2 minutes at 40 C, and 1.5 minutes at 72 C and a final extension of 7 minutes at 72 C. PCR using SPF primers was performed in a final reaction volume of 40 lL containing 4 lL isolated DNA, 4 lL 10Â buffer, 3.2 lL each dNTP, 0.5 lL each of forward and reverse primers, and 2.5 U Taq DNA polymerase. PCR conditions were as follows: preheat for 1 minute at 94 C followed by 40 cycles of 1 minute at 94 C, 1 minute at 45 C, and 1 minute at 72 C and a final extension of 5 minutes at 72 C. All PCR amplifications were performed with appropriate positive and negative controls. The PCR products of MY09/11 and GP5þ/6þ were separated by electrophoresis in 1.8% agarose gel. The products of SPF were fractionated on 12% polyacrylamide gel electrophoresis.
Roche Linear Array Test for HPV Genotyping
HPV genotyping was performed using the Roche linear array (LA) testing kit (Roche Molecular Diagnostics) according to the manufacturer's recommendations. This method can detect 37 different HPV types, 13 high-risk and 13 low-risk HPV types, seven possibly carcinogenic types, and four undetermined types (6, 11, 16, 18, Briefly, a portion of the purified DNA used for HPV PCR detection was used for genotyping. Then, 10 lL template DNA was amplified and products were hybridized and detected using an automated auto-line probe assay (LiPA) staining system (Innogenetics, Ghent, Belgium) using 2.5 mL of each reagent per strip. The LA results on the strips were evaluated by two independent observers. An unambiguous, continuous band was judged to indicate a positive result.
Statistical Analysis
The difference in HPV positivity rates between histologic types of cancer was analyzed by the Fisher exact test. Pearson correlation test was performed on the results of HPV and cytology tests. All analyses were performed by SPSS software (version 16.0; SPSS, Chicago, IL). A P value less than .05 (two-sided test) was considered significant.
Results
Twenty (32.8%) of the 61 cases with sufficient DNA were positive for HPV by PCR using GP5þ/6þ primer set, 22 (36.1%) were positive using MY9/11 primers, and 22 (36.1%) were positive using SPF1/2 primers. In total, 17 (27.9%) were positive for HPV using all three primer sets. Overall, HPV DNA was detectable in 27 (44.3%) cases using at least one of the three PCR primer sets Table 2 . Representative PCR results are shown in Image 2 .
Roche LA genotyping was also performed to examine HPV status and determine HPV genotypes in the 61 cancer specimens. The LA test detected HPV in 27 (44.3%) cases. One case was positive for HPV by the LA test but negative by PCR using all three PCR primer sets while one case was positive for HPV by PCR (GP5þ/6þ and SPFþ, MY9/11-) but negative by the LA test. Therefore, when all four methods are considered, HPV was detected in 28 (45.9%) of 61 total cases. A total of seven different HPV genotypes were identified. All but one case was positive for a single HPV genotype, and both HPV 26 and 58 were detected in this case. Of the positive cases, the most common genotype was HPV 16 (18/27, 66.7%), followed by HPV 58 (14.8%). Twenty-five cases were positive for carcinogenic HPV (hrHPV) types, and two cases were positive for HPV with possible carcinogenic risk (types 26 and 73) Table 3 . HPV 26 and 73 were not detected by the HC2 method.
When stratified by histologic type, HPV DNA was detected in half of squamous cell carcinomas (25/50) and two of three adenosquamous carcinoma surgical specimens. In contrast, HPV DNA was detected in only one (12.5%) of eight cervical adenocarcinoma surgical specimens Table 4 .
Among these 61 patients with invasive cervical cancer and prior negative HPV testing on cytology specimens, 44 patients had available Pap cytology findings within 1 year before histologic diagnosis. As shown in Table 5 , HPV DNA was detected in only one of four surgical specimens categorized as atypical glandular cells (AGCs) on prior cytology (25%) but in four (50%) of eight surgical specimens categorized as squamous cell carcinoma on preceding cytology and 10 (58.8%) of 17 categorized as high-grade squamous intraepithelial lesion. Notably, HPV DNA was actually detected in three (42.9%) of seven surgical specimens with both prior negative Pap test results and negative HPV testing on the cytologic specimens (Table 5) . Table 6 summarizes the Pap cytology results and HPV test results in both cytology and surgical specimens for all eight invasive cervical adenocarcinoma cases. As expected, no HPV DNA was detected in the two minimal deviation carcinoma and one clear cell carcinoma cases. When only the five cases of usual-type adenocarcinoma are considered, all three with Pap cytology results in the preceding year were categorized as AGC, all five had negative HC2 results on the cytology specimen, and only one of five was positive for HPV on the surgical resection specimen.
Discussion
To our knowledge, this is the first study to examine the ability to detect HPV DNA by PCR and LA methods in surgical tissues from patients with invasive cervical carcinoma with prior negative HC2 HPV testing on cytology before histologic diagnosis. The negative rates for HPV testing performed on cytology specimens from patients with invasive cervical cancer have varied widely in previous studies. [5] [6] [7] [8] [9] [10] [11] [12] [13] Our recent studies from China, together with several studies from the United States, demonstrated the HPV-negative rates ranged from 8% to 19% with an average of 14% on cytology specimens. 13, 14, [17] [18] [19] HPV DNA was detected in 28 (45.9%) of 61 surgical specimens, and HPV 16 was the most common HPV genotype detected in our cohort (66.7% of all HPV-positive cases), followed by HPV 58 (14.8%).
As the HC2 HPV testing method used on cytology specimens was only able to detect 13 hrHPV types (16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59, and 68), the cases shown to The potential reasons for negative hrHPV testing in the setting of cervical cancer screening include sampling variability, low viral load in some cancers, rapidly developing cervical carcinomas that arise between screening intervals, and the rare occurrence of true hrHPV-negative cervical adenocarcinomas. By examining the presence of HPV in the corresponding surgical resections of these previously reported patients having prior HPV-negative cytology samples, we show that "true" false-negative testing results represent almost half of these cases but also that true-negative results account for more than half of cases. Those cases with "true" false-negative results on cytology specimens (ie, HPV was not detected on cytology but was present in the resected carcinoma) most likely represent an inherent technical limitation in the testing of cytologic samples and can be explained by either low viral load below the limit of detection for the assay or as a result of limited sampling (ie, sampling error). Although it cannot be entirely excluded that some of these cases represent rapidly developing cancers that developed between the time of screening and surgical resection, this is unlikely given the short interval between screening and histologic diagnosis.
In contrast, more than half of cases did not contain detectable HPV DNA in the surgically resected tumors, and therefore the prior HPV testing for these patients actually represents a true-negative result. These cases demonstrate the limits in the strategy of screening women with HPV testing alone as a first-line test since at least a small percentage of cervical cancers is not etiologically related to HPV infection.
When considering the histologic type of cervical carcinoma, HPV-negative rates for Pap cytology specimens from patients with cervical adenocarcinoma were higher than those from squamous cell carcinoma or adenosquamous carcinoma. Potential reasons for the higher HPVnegative rates in cervical adenocarcinoma include the fact that cervical adenocarcinoma is more often focal and/or located higher in the endocervical canal and therefore more frequently eludes detection. Another explanation for this phenomenon is that cervical adenocarcinomas are not as often etiologically related to HPV infection, and therefore HPV testing will never detect some cases of adenocarcinomas. This is especially true in variants such as minimal deviation carcinoma and clear cell carcinoma. A recent analysis of 760 paraffin-embedded samples of cervical adenocarcinoma using an HPV genotyping method demonstrated HPV positivity of 71.8% for the usual type of adenocarcinoma but considerably lower rates for these unusual types. 21 Similarly, our data demonstrated that HPV DNA was detected in only 12.5% of surgical specimens from patients with cervical adenocarcinoma who had a negative HPV test on cytology specimens. This is much lower than that seen in the patients with cervical squamous cell carcinoma or adenosquamous cell carcinoma (50.9%, 27/53) and highlights the concern for the potential to miss greater numbers of patients with cervical adenocarcinoma in an HPV-only screening program. In addition, although Pap cytology screening also has limitations in the detection of glandular lesions, half of the cases of adenocarcinoma in this series with prior negative HPV results on a cytology sample were designated as AGC, and this includes all four cases with prior cytology results, and only one of four cases categorized as AGC by cytology had positive HPV results. In summary, our findings prove that prior negative HPV testing results on cytology specimens in patients with invasive cervical cancer are due to both false-negative test results in tumors with HPV and truly negative HPV testing in tumors lacking HPV. As others have shown, certain types of carcinomas are not etiologically related to HPV infection, including unusual types of cervical adenocarcinoma. Tumors that are related to HPV infection are likely missed on cytology HPV testing due to low viral titer, low viral genome copy number, sampling error, or the presence of rare HPV types that cannot be detected by current HPV testing methods.
